Advanced Accelerator Applications USA Inc.

Advanced Accelerator Applications USA Inc., a foreign-owned Novartis subsidiary headquartered in Millburn, New Jersey, manufactures and supplies specialized radiopharmaceuticals for nuclear medicine applications as a prime contractor to federal healthcare agencies, with no small business set-aside designations across its portfolio. The company is a large for-profit manufacturer primarily classified under NAICS 325412 (Pharmaceutical Preparation Manufacturing) and delivers lutetium Lu 177-based targeted radioligand therapies and gallium Ga 68 diagnostic imaging agents to the Department of Veterans Affairs, Defense Health Agency, National Institutes of Health, and Department of Defense medical facilities.

Advanced Accelerator Applications USA Inc.'s federal customer base centers heavily on the Veterans Affairs system. The top five customers by potential value account for approximately 61 percent of combined award value: VISN 9 anchors the portfolio with $53 million across nine awards (dominated by a single $49.1 million blanket purchase agreement running through December 2029 for PLUVICTO supply), followed by the National Acquisition Center with $23.4 million (a now-terminated BPA for LOCAMETZ and NETSPOT), VISN 10 with $22.7 million across thirty awards, VISN 21 with $21.9 million across twenty-seven awards, and VISN 12 with $20.8 million across thirty-one awards. By award count, VISN 22 leads with thirty-five awards valued at $15.2 million, the Navy's Bureau of Medicine and Surgery holds thirty-three awards valued at $572 thousand, and the Defense Health Agency maintains twenty-nine awards worth $15.9 million. This customer concentration reflects Advanced Accelerator Applications USA Inc.'s established position as the primary federal supplier of these specialized radiopharmaceuticals, which carry regulatory and manufacturing barriers to entry.

The vendor's primary contract vehicle is the GSA Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), through which 145 task orders totaling $199.6 million in combined potential value have been placed. Beyond the master schedule, Advanced Accelerator Applications USA Inc. holds multiple single-award blanket purchase agreements directly with VA service networks and other agencies. The VISN 9 BPA ($49.1 million through December 2029) represents the largest individual vehicle, followed by a $23.4 million National Acquisition Center BPA (now closed per a recent modification), a $7.5 million VISN 15 BPA running through February 2028, a $7.8 million VISN 12 BPA (completed), a $6.9 million VISN 10 BPA through September 2025, and a $6 million VISN 20 BPA through December 2026. Additional smaller BPAs support VISN 2, VISN 21, and the Defense Health Agency, each valued between $1.5 million and $2 million.

Representative contract work includes a $5.18 million delivery order from VISN 10 awarded January 1, 2025, for lutetium-based PLUVICTO and LUTATHERA supply through December 2025; a $3.49 million delivery order from VISN 22 awarded November 1, 2024, for PLUVICTO and LUTATHERA with completion October 31, 2025; a $3.99 million delivery order from VISN 21 awarded October 1, 2024, for PLUVICTO targeted radioligand therapy for prostate cancer treatment; and a $2.9 million BPA call from VISN 9 awarded December 20, 2024, for PLUVICTO supply. These orders exemplify the vendor's core capability: firm fixed-price supply of FDA-approved lutetium Lu 177 radiopharmaceuticals (PLUVICTO for prostate cancer, LUTATHERA for neuroendocrine tumors) and gallium Ga 68 diagnostic agents (NETSPOT) to federal medical centers on an as-needed basis through GSA schedule and BPA vehicles.

Activity has remained stable at thirty-plus awards annually from 2022 through 2024 (thirty-two, thirty-five, and thirty-five awards respectively), then declined to eleven awards in 2025 with a single award recorded through mid-July 2026. Combined potential value across all 328 awards totals $231.5 million, with $87.6 million obligated (38 percent realization rate). Within the next twenty-four months, three awards totaling $5.7 million face completion and potential recompete. The vendor operates exclusively as a prime contractor; no subcontract awards appear in the source data. Advanced Accelerator Applications USA Inc. registered as a federal contractor in January 2004 and maintains direct supply relationships across twenty-two distinct federal agencies, with the Veterans Health Administration and Defense Health Agency as predominant customers.